Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate â rather than block or over-activate â NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. Drugs that modulate NMDA receptors in this distinct way have both robust efficacy and favorable safety. The company currently has three product candidates in clinical development. NYX-2925 is in Phase 2 clinical development as a non-opioid therapy for chronic pain with fast-track designation in painful diabetic peripheral neuropathy (DPN), NYX-783 is in Phase 2 clinical development with fast-track designation for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase 1 clinical development for the treatment of cognitive impairment in Parkinsonâs disease. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.
Source
